AmpiProbe HCV utilizes the company’s proprietary nucleic acid amplification technology.
The company said upon approval, it will commercialize its AmpiProbe HCV assay for viral load determination through its clinical laboratory.
Enzo Biochem president Barry Weiner said the company’s studies indicate that AmpiProbe based assays can provide superior testing methodology through operational efficiency and economy than any similar platform currently available on the market.
"By providing cost savings to clinical laboratories as well as potential benefits to medical practices, we believe that our AmpiProbe platform can lead to a new generation of nucleic-acid based assays," Weiner added.
